Inclusion Criteria:

- Male or female patients of ≥ 18 years of age.

- Patients with a documented histologic diagnosis of relapsed or refractory
glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed
oligoastrocytoma (AOA). All patients will have samples of their tissue evaluated for
EGFRvIII overexpression and PTEN loss.

- Patients with a histologically confirmed low grade brain tumor who relapse with an
enhancing tumor on magnetic resonance imaging (MRI) can be evaluated for toxicity
only.

- Patients must have at least one confirmed and evaluable tumor site.*

*A confirmed tumor site is one which is biopsy-proven. NOTE: Radiographic procedures
(e.g., Gd-enhanced MRI or computed tomography [CT] scans) documenting existing
lesions must have been performed within three weeks of treatment on this research
study.

- Patients must have a Karnofsky performance status ≥ 60% (or the equivalent Eastern
Cooperative Oncology Group [ECOG] level of 0-2) and an expected survival of ≥ three
months.

- No chemotherapy for six weeks prior to treatment under this research protocol and
no external beam
radiation for eight weeks prior to treatment under this research protocol.

- Patients must have adequate hematologic reserve with WBC ≥ 3000/mm3, absolute
neutrophils ≥ 1500/mm3 and platelets ≥ 100,000/mm3. Patients who are on Coumadin
must have a platelet count of ≥ 150,000/mm3

- Pre-enrollment chemistry parameters must show: bilirubin < 1.5X the institutional
upper limit of normal (IUNL); AST or ALT < 2.5X IUNL and creatinine < 1.5X IUNL.

- Pre-enrollment coagulation parameters (PT and PTT) must be ≤ 1.5X the IUNL.

- Concomitant Medications:

- Growth factor(s): Must not have received within 1 week of entry onto this study.

- Steroids: Systemic corticosteroid therapy is permissible in patients with
centrail nervous system (CNS) tumors for treatment of increased intracranial
pressure or symptomatic tumor edema. Patients with CNS tumors who are receiving
dexamethasone must be on a stable or decreasing dose for at least 1 week prior
to study entry.

- Study Specific: Patients on enzyme-inducing anticonvulsants will be changed to
non-enzyme inducing anticonvulsants or will not be allowed on this study.
Patients receiving proton pump inhibitor or H2 blockers will not be allowed on
study. Patients taking antacids will be allowed on study although they should
not take the antacid for two hours before or two hours after taking erlotinib.

- Patients must agree to use a medically effective method of contraception during and
for a period of three months after the treatment period. A pregnancy test will be
performed on each premenopausal female of childbearing potential immediately prior to
entry into the research study.

- Patients should not have received a CYP3A4 inhibitor within 1 week of study entry and
should not have received a CYP3A4 inducer within 4 weeks of study entry.

- Patients should not have received proton-pump inhibitors within 5 days of study entry
or H2 blockers within 2 days of study entry.

- Patients on steroids must receive prophylaxis for Pneumocystis carinii pneumonia
(PCP) with Bactrim, unless they have a history of allergy to sulfa drugs.

- Patients must be able to understand and give written informed consent. Informed
consent must be obtained at the time of patient screening.

Exclusion Criteria:

- Previous treatment with Tarceva®.

- Women who are pregnant or lactating.

- Women of childbearing potential and fertile men will be informed as to the
potential risk of procreation while participating in this research trial and will be
advised that they must use effective contraception during and for a period of three
months after the treatment period.

- Patients with significant intercurrent medical or psychiatric conditions that would
place them at increased risk or affect their ability to receive or comply with
treatment or post-treatment clinical monitoring.